Farxiga Class Action Lawsuit in New York

Farxiga (dapagliflozin), an SGLT2 inhibitor made by AstraZeneca, has been linked to serious injuries including diabetic ketoacidosis (DKA), Fournier’s gangrene (a severe genital infection), and kidney failure. Plaintiffs allege AstraZeneca failed to adequately warn patients and doctors about these risks despite internal knowledge of the dangers. Litigation has proceeded in both federal MDL courts and individual state courts across the country.

New York residents who were prescribed Farxiga and suffered serious injuries—such as DKA, Fournier’s gangrene, or acute kidney injury—may qualify to bring a claim. Eligibility generally requires documented medical records linking Farxiga use to the injury, proof that you were prescribed the drug, and that you file within New York’s statute of limitations. A personal injury attorney can evaluate whether your specific facts support a viable claim.

Compensable injuries in Farxiga litigation typically include hospitalizations for diabetic ketoacidosis, surgical treatment of Fournier’s gangrene (which can result in permanent disfigurement), acute kidney damage requiring dialysis, and wrongful death where a loved one died as a result. Damages may cover medical expenses, lost wages, pain and suffering, and long-term care costs. No outcome is guaranteed and each case turns on its own evidence.

Under CPLR §214, New York imposes a 3-year statute of limitations on most personal injury claims, including pharmaceutical drug injury cases. The clock generally begins to run when you knew or reasonably should have known that your injury was caused by Farxiga—not necessarily the date you took the drug. Because delay can permanently bar your right to sue, consult a NY personal injury attorney as soon as possible if you believe Farxiga caused your injury.